Adjusted Tumor Enhancement on Dual-Phase Cone-Beam CT: Predictor of Response and Overall Survival in Patients with Liver Malignancies Treated with Hepatic Artery Embolization
Current Oncology · 2024
DOI: 10.3390/curroncol31060231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Hooman Yarmohammadi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Division of Interventional Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Cone-Beam Computed Tomography, Embolization, Therapeutic, Hepatic Artery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The aim of this study was to examine the value of tumor enhancement parameters on dual-phase cone-beam CT (CBCT) in predicting initial response, local progression-free survival (L-PFS) and overall survival (OS) following hepatic artery embolization (HAE). Between Feb 2016 and Feb 2023, 13 patients with 29 hepatic tumors treated with HAE were analyzed. Pre- and post-embolization, subtracted CBCTs were performed, and tumor enhancement parameters were measured, resulting in three parameters: pre-embolization Adjusted Tumor Enhancement (pre-ATE), post-embolization ATE and the difference between pre- and post-ATE (∆ATE). Treatment response was evaluated using the mRECIST criteria at 1 month. Tumors were grouped into complete response (CR) and non-complete response (non-CR) groups. To account for the effect of multiple lesions per patient, a cluster data analytic method was employed. The Kaplan–Meier method was utilized for survival analysis using the lesion with the lowest ∆ATE value in each patient. Seventeen (59%) tumors showed CR and twelve (41%) showed non-CR. Pre-ATE was 38.5 ± 10.6% in the CR group and 30.4 ± 11.0% in the non-CR group (p = 0.023). ∆ATE in the CR group was 39 ± 12 percentage points following embolization, compared with 29 ± 11 in the non-CR group (p = 0.009). Patients with ∆ATE > 33 had a median L-PFS of 13.1 months compared to 5.7 in patients with ∆ATE ≤ 33 (95% CI = 0.038–0.21) (HR, 95% CI = 0.45, 0.20–0.9, p = 0.04). Patients with ∆ATE ≤ 33 had a median OS of 19.7 months (95% CI = 3.77–19.8), while in the ∆ATE > 33 group, median OS was not reached (95% CI = 20.3-NA) (HR, 95% CI = 0.15, 0.018–1.38, p = 0.04). CBCT-derived ATE parameters can predict treatment response, L-PFS and OS following HAE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Division of Interventional Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
ORCID-Profile: Vlasios S Sotirchos, Mario Ghosn, Joseph P Erinjeri, Franz E Boas
Förderung
- NCI NIH HHS
Zitieren
APA
Yarmohammadi, H., Ridouani, F., Zhao, K., Sotirchos, V. S., Son, S. Y., Geevarghese, R., Marinelli, B., Ghosn, M., Erinjeri, J. P., Boas, F. E., & Solomon, S. B. (2024). Adjusted Tumor Enhancement on Dual-Phase Cone-Beam CT: Predictor of Response and Overall Survival in Patients with Liver Malignancies Treated with Hepatic Artery Embolization. Current Oncology. https://doi.org/10.3390/curroncol31060231
Vancouver
Yarmohammadi H, Ridouani F, Zhao K, Sotirchos VS, Son SY, Geevarghese R, et al. Adjusted Tumor Enhancement on Dual-Phase Cone-Beam CT: Predictor of Response and Overall Survival in Patients with Liver Malignancies Treated with Hepatic Artery Embolization. Current Oncology. 2024. doi:10.3390/curroncol31060231
BibTeX
@article{Yarmohammadi2024,
author = {Yarmohammadi, Hooman and Ridouani, Fourat and Zhao, Ken and Sotirchos, Vlasios S and Son, Sam Y and Geevarghese, Ruben and Marinelli, Brett and Ghosn, Mario and Erinjeri, Joseph P and Boas, Franz E and Solomon, Stephen B},
title = {Adjusted Tumor Enhancement on Dual-Phase Cone-Beam CT: Predictor of Response and Overall Survival in Patients with Liver Malignancies Treated with Hepatic Artery Embolization},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31060231}
}
EUVIMED